EMCURENSEEmcure Pharmaceuticals LimitedMediumNeutral
Announced Tue, 5 May · 15:58 IST

Revised intimation of Change in Management with minor correction in cover letter

Management Changes View source PDF

EMCURE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-1.9%1-day move
₹1689.00
prior close
₹1705.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-3.1-4.1-3.4-2.8-1.9-2.5-0.8-1.9-2.0+1.0+2.1+1.8+8.6
Up moveDown movePending
AI summary

Emcure Pharmaceuticals has announced the re-appointment of two key directors. Dr. Mukund Gurjar is re-appointed as Whole-time Director for 1 year from August 28, 2026, and Mr. Satish Mehta is re-appointed as Managing Director for 5 years from April 01, 2027. Both appointments are subject to shareholder approval. Dr. Gurjar has been with the company since 2001 and serves as Chief Scientific Officer. Mr. Satish Mehta is the founder and current Managing Director & CEO. The document also notes that Mr. Satish Mehta is father to two other Whole-time Directors on the board.

Likely market impact

This is a routine board continuity announcement. Existing leadership remains in place, which provides stability for shareholders. The re-appointments require shareholder approval but are expected to proceed smoothly.